Εμφάνιση απλής εγγραφής

dc.creatorIaccheri, B.en
dc.creatorAndroudi, S.en
dc.creatorBocci, E. B.en
dc.creatorGerli, R.en
dc.creatorCagini, C.en
dc.creatorFiore, T.en
dc.date.accessioned2015-11-23T10:30:13Z
dc.date.available2015-11-23T10:30:13Z
dc.date.issued2010
dc.identifier10.3109/09273941003739928
dc.identifier.issn0927-3948
dc.identifier.urihttp://hdl.handle.net/11615/28526
dc.description.abstractPurpose: To report a clinical case of a patient with severe scleritis associated with rheumatoid arthritis (RA) refractive to conventional treatment that was treated effectively with rituximab. Methods and Results: A 55-year-old man with RA, on etanercept and oral methotrexate, was referred with diagnosis of acute stromal keratitis, anterior uveitis, and anterior nodular scleritis in his right eye. Cyclophosphamide induced complete regression of acute stromal keratitis and anterior uveitis, but scleritis was still active and persistent. After two 1000-mg infusions of rituximab, scleritis regressed completely and is still in remission 9 months after the second rituximab infusion, without any concomitant use of oral steroids. Conclusion: Rituximab may be a treatment alternative in severe scleritis that is refractive to conventional therapy. Considering its safety profile, further studies are needed to refine its mechanism of action, optimal indications, and dosing in ocular inflammation.en
dc.sourceOcular Immunology and Inflammationen
dc.source.uri<Go to ISI>://WOS:000278910300017
dc.subjectrheumatoid arthritisen
dc.subjectrituximaben
dc.subjectscleritisen
dc.subjectWEGENERS-GRANULOMATOSISen
dc.subjectETANERCEPTen
dc.subjectEFFICACYen
dc.subjectTHERAPYen
dc.subjectOphthalmologyen
dc.titleRituximab Treatment for Persistent Scleritis Associated with Rheumatoid Arthritisen
dc.typejournalArticleen


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής